Your browser doesn't support javascript.
loading
What is the best time for postoperative radiation therapy in pN1 prostate cancer?
Mistretta, Francesco Alessandro; Luzzago, Stefano; Marvaso, Giulia; Corrao, Giulia; Sabatini, Ilaria; Fontana, Matteo; Mastroleo, Federico; Zaffaroni, Mattia; Vincini, Maria Giulia; Di Trapani, Ettore; Cozzi, Gabriele; Bianchi, Roberto; Ferro, Matteo; de Cobelli, Ottavio; Jereczek-Fossa, Barbara Alicja; Musi, Gennaro.
Afiliación
  • Mistretta FA; Department of Urology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Luzzago S; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
  • Marvaso G; Department of Urology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Corrao G; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
  • Sabatini I; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
  • Fontana M; Division of Radiation Oncology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Mastroleo F; Division of Radiation Oncology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Zaffaroni M; Department of Urology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Vincini MG; Department of Urology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Di Trapani E; Division of Radiation Oncology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Cozzi G; Department of Translational Medicine, University of "Piemonte Orientale", Novara, Italy.
  • Bianchi R; Division of Radiation Oncology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Ferro M; Division of Radiation Oncology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • de Cobelli O; Department of Urology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Jereczek-Fossa BA; Department of Urology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
  • Musi G; Department of Urology, European Institute of Oncology (IEO), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Milan, Italy.
Neoplasma ; 70(3): 458-467, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37498071
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Neoplasma Año: 2023 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Neoplasma Año: 2023 Tipo del documento: Article País de afiliación: Italia